A recent FNIH study demonstrates the effectiveness of non-invasive blood tests in diagnosing non-alcoholic steatohepatitis (NASH), potentially reducing the need for invasive liver biopsies and improving NASH diagnosis.
While biomarkers are integral to the identification and validation of disease treatment methods, there is a disconnect between existing validation approaches and their applications in commercialisation.
ICIs – immune checkpoint inhibitors – have changed the landscape of therapeutic treatment for cancer and improved survival rates for patients with advanced malignancies. However, the wide variability in clinical response is a significant limitation to treatment.
An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.
Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company's ultrasensitive biomarker assay technology.
23 March 2023
Biomarkers for Clinical Development
Search by Keyword
Filter by Subject Area
Filter by Content Type
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.